Aldeyra Therapeutics Inc
ALDX
NASDAQ
Biotechnology
$1.56
USD
+0.12 (+8.33%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $86.87M
Volume 830.0K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-23.05M
TTM
+54.5%
YoY
Operating Cash Flow
$-22.02M
TTM
+46.3%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 1.7 | 2.6 | 2.4 | 1.1 | 2.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 10.2 | 8.0 | 6.7 | 3.5 | 5.9 |
Operating Income | -10.2 | -8.0 | -6.7 | -3.5 | -5.9 |
EBITDA | -10.1 | -7.9 | -6.6 | -3.5 | -5.8 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 0.4 | 0.3 | 0.2 | 0.1 | 0.4 |
Income Before Income Taxes | -9.8 | -7.7 | -6.5 | -3.5 | -5.5 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -9.8 | -7.7 | -6.5 | -3.5 | -5.5 |
Consolidated Net Income / Loss | -9.8 | -7.7 | -6.5 | -3.5 | -5.5 |
Net Income Attributable to Common Shareholders | -9.8 | -7.7 | -6.5 | -3.5 | -5.5 |
Basic EPS | -$0.16 | -$0.13 | -$0.11 | -$0.06 | -$0.09 |
Diluted EPS | -$0.16 | -$0.13 | -$0.11 | -$0.06 | -$0.09 |
Basic Shares Outstanding | 60.0M | 60.1M | 60.2M | 60.3M | 60.3M |
Diluted Shares Outstanding | 60.0M | 60.1M | 60.2M | 60.3M | 60.3M |